Building the drug asset marketplace of the future by empowering biopharma to accelerate drug pipelines, maximize return on investment, and achieve clinical and commercial success for greater patient impact.

Enabling investors and biopharma to effectively position and showcase asset value during portfolio strategy planning and dealmaking.

Equipping investors with data-driven insights to optimize capital allocation in drug asset transactions.

The Prudentia Platform enables AI-powered Asset Diligence and Valuation to De-Risk Investment in Drug Development.

Real-time data-driven simulation and scenario planning to optimize asset valuation for deal terms and enable speed to decision leading to increased deal throughput.

Rapid AI-powered synthesis of data room into an asset assessment framework and product profile, which enables comparison with public and proprietary data and benchmarks to optimize development plan, determine asset risks and value drivers.

AI-guided product profiles and asset valuations to guide portfolio strategy and decision-making.

Multi-disciplinary expert in-the-loop deal analysis and modeling with real-time analytics to enable AI-accelerated insight across multiple dimensions of asset value and risk.

CEO & Founder: Sadiqa Mahmood (LinkedIn: https://www.linkedin.com/in/sadiqamahmood/)

Chief Technology Officer: John Reynders, PhD (LinkedIn: https://www.linkedin.com/in/john-reynders-5383b53/)

Head of Engineering: Pranathi Vangeepuram (LinkedIn: https://www.linkedin.com/in/pranathivangeepuram/)

Senior Data Scientist: Duc Do, PhD (LinkedIn: https://www.linkedin.com/in/doduc/)

Senior Software Engineer: Benjamin Fleming (LinkedIn: https://www.linkedin.com/in/ben7fleming/)

Senior Data Engineer: Alex Dreo (LinkedIn: https://www.linkedin.com/in/alex-dreo/)

Founding Board Member: Wasim Malik, PhD (LinkedIn: https://www.linkedin.com/in/wqmalik/)

LinkedIn: https://www.linkedin.com/company/prudentiasciences/

Job posts URL: Not explicitly found on the site